GHX Expands Executive Leadership Team to Support Growth in Healthcare Supply Chain, Data and Services Markets

Published on:

LOUISVILLE, Colo. – October 16, 2018 – Global Healthcare Exchange, LLC(GHX), a healthcare business and data automation company, has added two senior executives to support and amplify the company’s growth plans. New executives include Bob McCarthy, senior vice president of Strategy and Corporate Development and Laura Dunbar, senior vice president of Global Marketing.

“GHX continues on a growth trajectory, acquiring three companies in the past four years while also delivering critical new technology to help our clients solve the cost/quality equation in healthcare. Our mission to help improve the cost of delivering patient care is at the core of all our decisions. Expanding our leadership team continues our commitment to deepening engagement with our customers while expanding our market presence, and continuing to deliver solutions that transform the business of healthcare,” said Bruce Johnson, president and CEO, GHX. 

McCarthy joins GHX with more than 20 years of experience leading corporate development and strategy teams. Most recently, he worked for Level 3 Communications leading the company’s Corporate Development group in Broomfield, Colo. Prior to that he led other corporate development functions and held administrative leadership roles for companies such as BellSouth and Cypress Communications. McCarthy earned his bachelor’s degree and Juris Doctorate from the University of Carolina, Chapel Hill.

Dunbar will lead Global Marketing at GHX and most recently was Vice President of Marketing at GetWellNetwork, a Bethesda, MD provider of patient engagement technology solutions. Additionally, Dunbar has held marketing and leadership roles at West Corporation, where she was Vice President Marketing Strategy for the healthcare practice and VMware, where she led product marketing for the company’s IT Business Management and IT Benchmarking solutions. Dunbar earned her master’s in Business Administration from San Jose State University, San Jose, Calif, and bachelor’s from the University of Colorado, Colorado Springs, Colo.

About GHX

Global Healthcare Exchange, LLC (GHX) is a healthcare business and data automation company, empowering healthcare organizations to enable better patient care and maximize industry savings using its world-class cloud-based supply chain technology platform. GHX brings together healthcare providers, manufacturers and distributors in North America, and Europe, who rely on proven healthcare-focused technology and comprehensive data to automate business processes and make more informed, timely and fact-based decisions. Solutions span procurement and accounts payable automation, contract and inventory management, vendor credentialing and management, business intelligence, payment management and other supply chain-related tools and services. 

Related Content

FDA issues Class I recall on counterfeit infusion pump batteries
FDA issues alert on PCNL sheath safety after patient death
DOJ sues CVS over unlawful opioid prescriptions and reimbursement
Bipartisan bills in Congress would force insurance companies, PBMs to sell pharmacies
FDA recalls 233K bottles of antidepressants due to cancer risk
FDA issues Class I recall on insulin syringes due to risk of death

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.